LiDCO Group Plc
02 March 2005


For immediate release                                             2 March 2005



                                LiDCO GROUP PLC

                              CHANGE OF PR COMPANY



LiDCO Group plc (AIM: LID), the UK-based cardiovascular monitoring company, is
pleased to announce the appointment of Buchanan Communications as its financial
PR company.



Buchanan is a financial communications agency with a market leading position in
the healthcare and medtech arena.



For more information please contact:
  LiDCO Group Plc                                                  020 7749 1500
  Terry O'Brien, CEO (terry@lidco.com)
  Theresa Wallis, Chairman (theresa.wallis@lidco.com)

Buchanan Communications
 Tim Anderson, Mary-Jane Johnson, James Strong                     020 7466 5000
 
Durlacher Ltd
 Grant Harrison (Head of Corporate Broking)                        020 7459 3600



Notes for Editors:

LiDCO is a leading supplier of minimally invasive, computer-based hemodynamic
monitoring equipment and disposables used primarily for the management of
critical care and cardiovascular risk hospital patients.

The Company's current products are:

  • the LiDCOplus and PulseCO monitors, computer-based platforms for
    displaying a range of real-time continuous hemodynamic parameters including
    cardiac output, oxygen delivery and fluid volume following calibration with:

  • the LiDCO disposable for accurately determining cardiac output in a
    minimally-invasive manner



Application of the LiDCO technology to reduce complications and costs of
surgery:

Post surgical 'Goal Directed Optimisation' is an application of the LiDCOplus
monitor. The 'Goal' is to target a higher than normal delivery of the oxygen
carried by the blood's red cells to the body tissues. Achievement of this 'Goal'
has been shown to reduce the complications associated with surgery. To achieve '
Goal Directed Optimisation' the LiDCOplus monitor measures the absolute and beat
to beat changing levels of oxygen delivery through use of an arterial line
already inserted in a small vessel at the wrist of most major surgery patients.
The monitor user interface has been specifically designed to help the clinician
or nurse to rapidly and appropriately administer intra venous fluids and drugs
that increase oxygen delivery to levels that ensure the repayment of any oxygen
deficit incurred during major surgery. The advantages of using the LiDCOplus
technology are that the oxygen delivery targets can be both set and achieved
minimally invasively using existing staff without the use of more invasive
catheters that have additional risks to the patient and costs to the hospital.


                      This information is provided by RNS
            The company news service from the London Stock Exchange